Advances in Molecular Diagnostics of Infectious Diseases

Bio-Rad Laboratories, Inc. a provider of life science research and clinical diagnostic products, have announced the launch of Amplichek STI quality control, the third in a series of molecular infectious disease quality controls that the company has introduced for the molecular testing market.

Amplichek STI is a multi-analyte quality control product that monitors the performance of in vitro laboratory nucleic acid testing procedures for the detection of Sexually Transmitted Infections including Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG or GC), and high risk strains of human papillomavirus (HPV). Amplichek STI is the only available IVD product that includes CT, NG/GC, and HPV and is designed to monitor analytical processes that include nucleic acid extraction and amplification in one control.

Molecular diagnostics is one of the fastest growing markets for in vitro diagnostics (IVD), with nucleic acid testing for Sexually Transmitted Infections (STI) expected to reach over $1.3B by 2020, according to a 2015 report by research firm MarketsandMarkets.